Biomarkers as surrogate end points in heart failure trials.


Journal Article (Review)

Despite the continued growth of heart failure as a major public health problem, the development of new therapies for heart failure has slowed and recent studies have been neutral, suggesting the need for a reappraisal of the clinical research enterprise. Surrogate end points, defined as measurements that are used as substitutes for the more clinically meaningful end points, can play a valuable role in clinical trials by accelerating the timeline for determining appropriate dosages, efficacy, and safety. Biomarkers, such as the natriuretic peptides, have many of the characteristics of valid surrogates but have not been sufficiently validated for widespread use. Ongoing research into the role of biomarkers as surrogates may lead to better clinical trial design and more efficient development of new therapies for heart failure.

Full Text

Duke Authors

Cited Authors

  • Felker, GM

Published Date

  • October 2011

Published In

Volume / Issue

  • 7 / 4

Start / End Page

  • 501 - 507

PubMed ID

  • 21925433

Pubmed Central ID

  • 21925433

International Standard Serial Number (ISSN)

  • 1551-7136

Digital Object Identifier (DOI)

  • 10.1016/j.hfc.2011.06.001


  • eng

Conference Location

  • United States